LD-2 disclosure · 1st Quarter - Report
EDISON PHARMACEUTICALS
Income$20Kfee reported
Client
- Description
- Drug development for treatment of rare mitochondrial disease, TBI, and TON
- Location
- California · United States of America
Registrant
- Description
- Global trade
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
2 issuesDefense
Defense Appropriations Act, developmental funding for therapeutics for hereditary and acquired mitochondrial diseases.
LobbyistsELIZABETH BARROWS
TargetedDefense, Dept of (DOD) · Defense Advanced Research Projects Agency (DARPA)
Health Issues
Defense Appropriations Act, developmental funding for therapeutics for hereditary and acquired mitochondrial diseases.
LobbyistsELIZABETH BARROWS
TargetedDefense, Dept of (DOD) · Defense Advanced Research Projects Agency (DARPA)